Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery

被引:0
|
作者
Li, Qingxin [1 ]
Kang, Congbao [2 ]
机构
[1] Guangdong Acad Sci, Inst Biol & Med Engn, Guangdong Prov Engn Lab Biomass High Value Utiliza, Guangzhou 510316, Peoples R China
[2] ASTAR, Expt Drug Dev Ctr EDDC, 10 Biopolis Rd,05-01, Singapore 138670, Singapore
来源
MOLECULES | 2024年 / 29卷 / 23期
关键词
F-19-NMR; fragment screening; drug discovery; fragment-based drug design; in-cell F-19-NMR; OBSERVED FLUORINE NMR; PROTEIN-PROTEIN INTERACTIONS; LIGAND BINDING; STD NMR; RNA; SPECTROSCOPY; IDENTIFICATION; TOOL; QUANTIFICATION; VALIDATION;
D O I
10.3390/molecules29235748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fragment-based drug discovery is a powerful approach in drug discovery, applicable to a wide range of targets. This method enables the discovery of potent compounds that can modulate target functions, starting from fragment compounds that bind weakly to the targets. While biochemical, biophysical, and cell-based assays are commonly used to identify fragments, F-19-NMR spectroscopy has emerged as a powerful tool for exploring interactions between biomolecules and ligands. Because fluorine atoms are not naturally present in biological systems, F-19-NMR serves as a sensitive method for fragment screening against diverse targets. Herein, we reviewed the applications of F-19-NMR in fragment screening, highlighting its effectiveness in identifying fragments that bind weakly to various targets such as proteins and RNA. The accumulated evidence suggests that F-19-NMR will continue to be a crucial tool in drug discovery.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors
    Svensson, Fredrik
    Bender, Andreas
    Bailey, David
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (04) : 1415 - 1424
  • [32] Ligand efficiency and fragment-based drug discovery
    Bembenek, Scott D.
    Tounge, Brett A.
    Reynolds, Chades H.
    DRUG DISCOVERY TODAY, 2009, 14 (5-6) : 278 - 283
  • [33] Fragment-based drug discovery through tethering
    Erlanson, DA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2763 - U2763
  • [34] What is the future for fragment-based drug discovery?
    Keseru, Gyorgy M.
    Hann, Michael M.
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (13) : 1457 - 1460
  • [35] Advances in fragment-based drug discovery platforms
    Orita, Masaya
    Warizaya, Masaichi
    Amano, Yasushi
    Ohno, Kazuki
    Niimi, Tatsuya
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (11) : 1125 - 1144
  • [36] What makes a good fragment in fragment-based drug discovery?
    Konteatis, Zenon
    EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (07) : 723 - 726
  • [37] Fragment-based QSAR: perspectives in drug design
    Salum, Livia B.
    Andricopulo, Adriano D.
    MOLECULAR DIVERSITY, 2009, 13 (03) : 277 - 285
  • [38] Fragment-based QSAR: perspectives in drug design
    Lívia B. Salum
    Adriano D. Andricopulo
    Molecular Diversity, 2009, 13 : 277 - 285
  • [39] Fragment-Based Lead Discovery Strategies in Antimicrobial Drug Discovery
    Konaklieva, Monika I.
    Plotkin, Balbina J.
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [40] Current perspectives in fragment-based lead discovery (FBLD)
    Lamoree, Bas
    Hubbard, Roderick E.
    STRUCTURE-BASED DRUG DESIGN: INSIGHTS FROM ACADEMIA AND INDUSTRY, 2017, 61 (05): : 453 - 464